Press release
Top Market Shifts Transforming the Empagliflozin, Dapagliflozin And Canagliflozin Market Landscape: Key Insights
Empagliflozin, Dapagliflozin And Canagliflozin
What Is the Expected CAGR for the Empagliflozin, Dapagliflozin And Canagliflozin Market Through 2025?
In recent times, the market size for empagliflozin, dapagliflozin, and canagliflozin has consistently expanded. Projected growth suggests an increase from $9.64 billion in 2024 to $9.94 billion in 2025, marking a compound annual growth rate (CAGR) of 3.1%. This growth during the historic period is likely due to several factors, including a global rise in type 2 diabetes cases, heightened awareness regarding the benefits of SGLT2 inhibitors, an increase in the senior population, the escalating prevalence of obesity, and a growing emphasis on personalized medicine.
What's the Projected Size of the Global Empagliflozin, Dapagliflozin And Canagliflozin Market by 2029?
We can anticipate consistent expansion in the market size of empagliflozin, dapagliflozin and canagliflozin over the upcoming years. By 2029, the market is predicted to reach an estimate of $11.06 billion with a Compound Annual Growth Rate (CAGR) of 2.7%. The projected expansion during this period is tied to a rising demand for oral medications for diabetes, increased funding in diabetes research and drug creation, escalating healthcare costs, increased recognition and diagnosis of conditions prior to diabetes, and emphasis on combination therapies. Key trends to watch in this forecast period include innovations in technology, combination therapies, telehealth services, health information analytics, and security of patient data.
View the full report here:
https://www.thebusinessresearchcompany.com/report/empagliflozin-dapagliflozin-and-canagliflozin-global-market-report
Top Growth Drivers in the Empagliflozin, Dapagliflozin And Canagliflozin Industry: What's Accelerating the Market?
The escalating number of diabetes cases worldwide is anticipated to boost the expansion of the market for empagliflozin, dapagliflozin, and canagliflozin. Diabetes, characterized by high blood sugar levels due to insufficient insulin production or poor insulin usage, remains a pressing health concern. The surge in diabetes cases can be linked to factors like inactive lifestyles, poor eating habits, inherited genetic traits, increasing urbanization, and an aging global population. These factors are worsened by limited healthcare accessibility and increasing global obesity rates. Treatments for diabetes, such as empagliflozin, dapagliflozin, and canagliflozin, help to decrease sugar levels in the bloodstream by blocking the sodium-glucose co-transporter-2 (SGLT2) in the kidneys, facilitating glucose excretion via urination. For example, the National Health Service (NHS) released data in June 2024 showing a dramatic increase in diabetes cases among individuals under 40, from 173,166 in 2022 to 216,440 in 2023. This significant increase underscores a worrying trend among this demographic, indicating a steep rise in the occurrence of diabetes. Consequently, this rise in diabetes prevalence is catalyzing the expansion of the empagliflozin, dapagliflozin, and canagliflozin market.
Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=18350&type=smp
What Trends Will Shape the Empagliflozin, Dapagliflozin And Canagliflozin Market Through 2029 and Beyond?
Key players in the markets for empagliflozin, dapagliflozin, and canagliflozin are concentrating their efforts on the creation of groundbreaking products such as treatments for pediatric type-2 diabetes. This approach aims to cater to a wider patient demographic and extend their influence in diabetes care. Managing pediatric type-2 diabetes involves maintaining blood sugar levels through lifestyle modifications, prescribed medication, and occasionally, tailor-made insulin therapy for children and teenagers. For instance, AstraZeneca, based in the UK, publicized in June 2024 that the US FDA endorsed its product Farxiga (dapagliflozin) to upgrade glycemic control in pediatric patients over ten years old with type 2 diabetes. This ratification followed the positive outcomes from the T2NOW Phase III clinical trial-one of the most comprehensive studies on pediatric type-2 diabetes-revealing that Farxiga considerably reduced HbA1c levels when compared to a placebo. The safety outline for Farxiga in this demographic paralleled those seen in adult patients with type-2 diabetes. This successful approval symbolizes a significant landmark as oral treatments for pediatric type-2 diabetes are scarce. Furthermore, it highlights AstraZeneca's commitment to providing ground-breaking treatments for cardiovascular, renal, and metabolic diseases.
What Are the Main Segments in the Empagliflozin, Dapagliflozin And Canagliflozin Market?
The empagliflozin, dapagliflozin and canagliflozin market covered in this report is segmented -
1) By Type: Empagliflozin, Dapagliflozin, Canagliflozin
2) By Application: Application I, Application II, Application III, Application IV
3) By Channel: Hospital, Pharmacy
Subsegments:
1) Empagliflozin: 10 Mg, 25 Mg, 50 Mg
2) Dapagliflozin: 5 Mg, 10 Mg
3) Canagliflozin: 100 Mg, 300 Mg
Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=18350&type=smp
Which Top Companies are Driving Growth in the Empagliflozin, Dapagliflozin And Canagliflozin Market?
Major companies operating in the empagliflozin, dapagliflozin and canagliflozin market are Pfizer Inc., Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline plc, Eli Lilly and Company, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., MSN Laboratories Private Limited, Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Cadila Healthcare Limited, Apotex Inc., Lupin Limited, Biocon Limited, Alkem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd.
Which Regions Will Dominate the Empagliflozin, Dapagliflozin And Canagliflozin Market Through 2029?
North America was the largest region in the empagliflozin, dapagliflozin and canagliflozin market in 2024. The regions covered in the empagliflozin, dapagliflozin and canagliflozin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18350
This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Top Market Shifts Transforming the Empagliflozin, Dapagliflozin And Canagliflozin Market Landscape: Key Insights here
News-ID: 4134677 • Views: …
More Releases from The Business Research Company
Metagenomics Market Research Reveals Path To $4.57 Billion By 2030
The metagenomics market is gaining significant attention as advances in technology and growing applications across various fields drive its expansion. With increasing investments and innovations, this sector is poised for substantial growth over the coming years. Here, we explore the market's valuation projections, key players, current trends, and segment analysis to paint a comprehensive picture of this dynamic industry.
Projected Market Size and Growth Trajectory of the Metagenomics Market
The…
Menopause Digital Hormone Balancing App Market Research Reveals Path To $3.34 Bi …
The menopause digital hormone balancing app sector is poised for impressive expansion as digital health solutions continue to transform personalized healthcare. With growing interest in tailored menopause management and technological integration, this market is set to evolve rapidly over the coming years. Let's explore the current market size, leading companies, emerging trends, and the detailed segmentation shaping its future.
Projected Growth Trajectory of the Menopause Digital Hormone Balancing App Market …
Metabolomics Market Demonstrates Long-Term Growth Potential At 17.3% CAGR
The metabolomics market is rapidly evolving, driven by technological advancements and increasing applications in healthcare and research. As this sector grows, it is set to transform personalized medicine and clinical diagnostics, offering new insights into disease mechanisms and therapeutic approaches. Here's a detailed overview of its projected growth, key players, emerging trends, and principal market segments.
Market Value Outlook and Growth Drivers in the Metabolomics Market
The metabolomics market is…
Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Outlook …
The metabolic dysfunction-associated steatohepatitis (MASH) treatment market is on the cusp of significant expansion, driven by scientific advancements and evolving therapeutic approaches. As awareness and diagnosis improve, this sector is set to witness rapid growth, fueled by innovative treatments and technology integration, promising better patient outcomes in the coming years.
Projected Market Value and Growth Trajectory for the MASH Treatment Market
The MASH treatment market is anticipated to reach a…
More Releases for Empagliflozin
Empagliflozin Impurity Standards: Ensuring Uncompromised Drug Quality with Preci …
Empagliflozin, a widely prescribed medication for managing Type 2 diabetes, has revolutionized the approach to treatment by enabling better glycemic control and reducing cardiovascular risks. As its demand grows, so does the need for impeccable quality standards to ensure its efficacy and safety for patients worldwide. Integral to achieving this is the availability of well-characterized impurity standards, which form the cornerstone for rigorous quality testing.
To meet these precise requirements, Empagliflozin…
Lizhuo Pharmaceutical Technology: Empagliflozin Intermediate 3 CAS NO. 1279691-3 …
Product Name:Empagliflozin Intermediate 3
Image: https://www.abnewswire.com/upload/2025/02/244d490e8e67be1fc6fd489f30405e07.jpg
CAS NO.:1279691-36-9
Synonyms:
Empagliflozin N-1;
(2S,3R,4S,5S,6R)-2-(3-(4-((S)-tetrahydrofuran-3-yloxy)benzyl)-4-chlorophenyl)-tetrahydro-6-(hydroxyMethyl)-2-Methoxy-2H-pyran-3,4,5-triol;
Methyl 1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]Methyl]phenyl]-alpha-D-glucopyranoside;
Related Categories:Empagliflozin intermediates; pharmaceutical raw materials; pharmaceutical intermediates; organic intermediates.
Appearance: White to Off-White solid
Purity: 98%
Application: Empagliflozin intermediates;pharmaceutical intermediate
Supply Ability
Empagliflozin Intermediate3 CAS NO.1279691-36-9 is our regularly production product, whether you need small sample or a large cargo of more than tonnage, our company can supply it formally
If you are interested in Empagliflozin Intermediate3 CAS NO.1279691-36-9, feel freely contact us please, and we will provide…
Empagliflozin, Dapagliflozin And Canagliflozin Market Report By Size, Share And …
The Business Research Company recently released a comprehensive report on the Global Empagliflozin, Dapagliflozin And Canagliflozin Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
Ready to Dive into Something Exciting? Get Your Free…
Empagliflozin, Dapagliflozin And Canagliflozin Market Size, Share Analysis And T …
The new report published by The Business Research Company, titled Empagliflozin, Dapagliflozin And Canagliflozin Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033, delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.
As per the report, the empagliflozin, dapagliflozin and canagliflozin market size has grown steadily in recent years. It will grow from…
Empagliflozin, Dapagliflozin and Canagliflozin Market Research Report 2023: …
Empagliflozin, Dapagliflozin and Canagliflozin are three main types of SGLT-2 inhibitors.
Global Empagliflozin, Dapagliflozin and Canagliflozin Market: Driven factors and Restrictions factors
The research report encompasses a comprehensive analysis of the factors that affect the growth of the market. It includes an evaluation of trends, restraints, and drivers that influence the market positively or negatively. The report also outlines the potential impact of different segments and applications on the market in the…
Empagliflozin Tablets Market Opportunities and Growth Challenges Report 2022-203 …
Global Empagliflozin Tablets Market 2022-2028 - Global Industry Size, Supply Analysis, Price Analysis, Consumption and Production, Supplier and Cost Structure Analysis
Empagliflozin Tablets Market Overview
The recent market intelligence study by the research analysts at Market Business Insights (MBI) takes a deep dive into inner operations of the global Empagliflozin Tablets Market. It thoroughly examines the market landscape to give the readers an accurate insight into the current, as well as the…
